Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuronetics (STIM)
:STIM
Holding STIM?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.19Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: 123.64%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment. While the company reported revenue growth and improved gross margins, challenges such as increased net loss and reduced revenue guidance indicate underlying difficulties. The Greenbrook acquisition and operational efficiencies are promising, but immediate financial pressures remain.Company Guidance
During the Neuronetics Q3 2024 earnings call, the company provided guidance on several key financial metrics and strategic initiatives. For the fourth quarter, Neuronetics anticipates stand-alone revenue of $19 million to $20 million, with a full-year projection between $71 million and $72 million. The company is focusing on achieving cash flow breakeven by the third quarter of 2025, driven by a strategic reorganization that aims to realize $20 million in cost synergies from the Greenbrook acquisition. This includes a $6 million reduction in marketing spend and savings from consolidating back-office functions. The gross margin for Q3 was reported at 75.6%, a significant increase from the previous year's 65.8%, attributed to changes in product mix and the absence of prior manufacturing costs. Operating expenses saw a 5% increase, primarily due to transaction expenses. Neuronetics is aggressively targeting profitable revenue growth through operational efficiencies and expanding service offerings, with plans to introduce SPRAVATO across all Greenbrook clinics by 2025.Revenue Growth
Total revenue for the third quarter of 2024 was $18.5 million, representing a 4% increase over the third quarter of 2023.
Gross Margin Improvement
Gross margin increased to 75.6% from 65.8% in the prior year quarter, an increase of 980 basis points.
Greenbrook Acquisition and Synergies
The Greenbrook acquisition was approved, with expected synergies increasing from $15 million to $20 million due to further operational efficiencies.
Operational Efficiency Initiatives
Implemented a strategic reorganization to reduce costs and optimize operations, expecting $3.5 million in annualized expense reduction.
SPRAVATO Expansion
Plans to expand SPRAVATO to all appropriate Greenbrook clinics by 2025, currently utilized in 83 sites.
---
STIM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
STIM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $1.10 | $0.69 | -37.27% |
| Aug 12, 2024 | $1.78 | $0.74 | -58.43% |
| May 07, 2024 | $3.75 | $2.60 | -30.67% |
| Mar 05, 2024 | $2.79 | $3.22 | +15.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Neuronetics (STIM) report earnings?
Neuronetics (STIM) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is Neuronetics (STIM) earnings time?
Neuronetics (STIM) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STIM EPS forecast?
STIM EPS forecast for the fiscal quarter 2024 (Q4) is -0.24.
---